Ali Tabatabaei
Overview
Explore the profile of Ali Tabatabaei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baltgalvis K, Lamb K, Symons K, Wu C, Hoffman M, Snead A, et al.
Nature
. 2024 Jul;
631(8021):E12.
PMID: 38961306
No abstract available.
2.
Baltgalvis K, Lamb K, Symons K, Wu C, Hoffman M, Snead A, et al.
Nature
. 2024 Apr;
629(8011):435-442.
PMID: 38658751
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with...
3.
Hudson A, Santora V, Petroski R, Almos T, Anderson G, Barido R, et al.
Bioorg Med Chem Lett
. 2020 Jun;
30(14):127214.
PMID: 32527538
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of...
4.
Chen J, Gu G, Chen M, Scott T, Heger L, Zook D, et al.
Neurochem Int
. 2020 Apr;
137:104735.
PMID: 32246980
Phosphodiesterase 7B (PDE7B) inhibition has been considered as a therapeutic target for the treatment of several neurological disorders. Currently, there are no radio-labeled tracers available to determine receptor occupancy (RO)...
5.
Jabbarvand M, Hashemian H, Khodaparast M, Jouhari M, Tabatabaei A, Rezaei S
Ophthalmology
. 2020 Mar;
127(4):557.
PMID: 32200842
This article has been retracted: please see Elsevier policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). The editors wish to note that concerns were raised regarding coding errors in the data set that...
6.
Gu G, Scott T, Yan Y, Warren N, Zhang A, Tabatabaei A, et al.
J Pharmacol Exp Ther
. 2019 Jun;
370(3):399-407.
PMID: 31253692
Inhibition of phosphodiesterase 2A (PDE2A) has been proposed as a potential approach to enhance cognitive functioning and memory through boosting intracellular cGMP/cAMP and enhancing neuroplasticity in memory-related neural circuitry. Previous...
7.
Chen J, Zook D, Crickard L, Tabatabaei A
Neurochem Int
. 2019 May;
129:104471.
PMID: 31121256
Phosphodiesterase (PDE) inhibition has been broadly investigated as a target for a wide variety of indications including central nervous system (CNS) disorders. Cyclic nucleotide (cNT) changes within associated tissues may...
8.
Santora V, Almos T, Barido R, Basinger J, Bellows C, Bookser B, et al.
J Med Chem
. 2018 Jun;
61(14):6018-6033.
PMID: 29886732
We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the...
9.
Chen J, Tabatabaei A, Zook D, Wang Y, Danks A, Stauber K
J Pharm Biomed Anal
. 2017 Sep;
146:361-368.
PMID: 28918326
A robust high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) assay was developed and qualified for the measurement of cyclic nucleotides (cNTs) in rat brain tissue. Stable isotopically labeled 3',5'-cyclic adenosine-C...
10.
Dyck B, Branstetter B, Gharbaoui T, Hudson A, Breitenbucher J, Gomez L, et al.
J Med Chem
. 2017 Apr;
60(8):3472-3483.
PMID: 28406621
A series of potent thienotriazolopyrimidinone-based PDE1 inhibitors was discovered. X-ray crystal structures of example compounds from this series in complex with the catalytic domain of PDE1B and PDE10A were determined,...